PT-141 - Driada Medical

Bremelanotide, sold as Vyleesi, is an FDA-approved option for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It activates melanocortin 1 and 4 receptors in the hypothalamus, linked to arousal and behavioral responses, triggering dopamine release to boost desire. Administered roughly 45 minutes before anticipated intimacy, this receptor-targeting therapy shows promise in enhancing desire and alleviating distress. While its precise action remains under investigation, research highlights its effectiveness in addressing low sexual drive, offering improved arousal and overall satisfaction for affected women.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about PT-141 by Driada Medical, consult with your doctor or healthcare professional.